IRON — Disc Medicine, Inc.
$74.51-0.69%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for IRON in the TickerWise workspace.
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 94
- Website: https://www.discmedicine.com
Latest SEC filings for IRON
Latest IRON news
- Disc Medicine sets $75 share price for $450M offering Read article
- Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock Read article
- Disc Medicine launches $350M public offering of common stock and pre-funded warrants Read article
- Disc Medicine surges on late-stage trial win for lead asset developed with Roche Read article
- Disc Medicine rallies 32% as investors await bitopertin trial results Read article
- Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) Read article
- ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Read article
- Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.